News Release

Researchers develop a promising gene-editing strategy for spinal muscular atrophy

Spinal Muscular Atrophy or SMA is the leading genetic cause of infant death worldwide

Peer-Reviewed Publication

Massachusetts General Hospital

Key Takeaways

  • Spinal muscular atrophy is a leading genetic cause of infant death worldwide, and is typically caused by loss-of-function mutations in the SMN1 gene, which produces the SMN protein
  • Gene therapy and small molecule treatments for spinal muscular atrophy (SMA) have led to extraordinary improvements for patients, but there is no definitive genetic cure
  • In lab models, the Mass General-led research team used a CRISPR-based approach to edit a comparable gene (SMN2) to produce the SMN protein, a strategy that may overcome limitations of current treatments

BOSTON—Spinal muscular atrophy (SMA) is a devastating pediatric neuromuscular disorder caused by loss-of-function mutations in the SMN1 gene, which prevents the body from producing enough of the survival motor neuron (SMN) protein that is important for development and neuronal function.

Motor neurons affected by SMA include those that control movement in the arms, legs, face, chest, throat and tongue, as well as those used in speaking, walking, swallowing and breathing.

While there are effective gene and molecular therapies that have led to remarkable improvements patients with SMA, there is still no definitive genetic cure that treats the root cause of this disease, and concerns about the longevity and efficacy of the current approaches remain.

Serendipitously, humans also encode gene called SMN2 that is similar to SMN1.

In a recent study published in Nature Biomedical Engineering, a research team led by Christiano Alves, PhD, and Benjamin Kleinstiver, PhD, developed a customized CRISPR base editor that “activates” SMN2 to restore SMN protein expression to normal levels irrespective of a patient’s SMN1 mutation.

The team validated the safety and efficacy of their approach in cell lines before delivering the treatment via an AAV viral vector into a mouse model of SMA.

They found that the treatment resulted in precise SMN2 editing in vivo, restoring the production of the SMN protein and improving disease symptoms.

“By developing a single genome editing strategy to correct SMN2 to enable high levels of SMN protein expression, our approach could avoid the need to correct different types of mutations in the SMN1 gene,” explains Kleinstiver, an Assistant Investigator at the Center for Genomic Medicine at Mass General, an Assistant Professor at Harvard Medical School, and Kayden-Lambert MGH Research Scholar 2023-2028.

“Although our results are the initial steps towards a longer-term goal, the optimization of a single editing approach to treat all patients could eventually streamline progress into the clinic”.

“Our approach to treat SMA by editing SMN2 followed the blueprint of approved SMA drugs. Continued development of our base editing approach should provide a long-lasting genetic treatment for SMA, where a durable one-time edit offers major advantages compared to existing therapies,” says Alves, the lead and co-corresponding author of the study. Alves is an Assistant Investigator at the Center for Genomic Medicine and an Instructor in Neurology at HMS.

There are several steps ahead to continue the development of these strategies towards a once-and-done therapy for SMA, including:

  • Testing the impact of a combinatorial therapy with other drugs approved for SMA treatment, to maximize efficacy.
  • Developing alternative delivery methods for these base editors which would require lower AAV doses, or non-viral delivery methods that could obviate concerns about the use of AAV.

The team notes that their results are complementary to another recent study from Arbab et al. (Science, 2023), where they undertook a similar approach to permanently edit SMN2 using base editors towards treating SMA.

Funding

This work was supported by a Charles A. King Trust Postdoctoral Research Fellowship, Bank of America, N.A., Co-Trustees (C.R.R.A.); a James L. and Elisabeth C. Gamble Endowed Fund for Neuroscience Research/Mass General Neuroscience Transformative Scholar Award (C.R.R.A.); a MGH Physician/Scientist Development Award (C.R.R.A.); a MGH Executive Committee on Research Fund for Medical Discovery Fundamental Research Fellowship Award(K.A.C.); a Frederick Banting and Charles Best Canadian Institutes of Health Research Doctoral Research Award (A.R.); a St. Jude Children’s Research Hospital Collaborative Research Consortium on Novel Gene Therapies for Sickle Cell Disease (S.Q.T.); a Muscular Dystrophy Association grant 575466 (R.K.); a Muscular Dystrophy Canada grant (R.K.); a Canadian Institutes of Health Research grant PJT-156379 (R.K.); an MGH Innovation Discovery Grant (to C.R.R.A. and B.P.K.); an MGH Executive Committee on Research Howard M. Goodman Fellowship (B.P.K.); and National Institutes of Health grants R01DC017117 (C.A.M.), U01AI157189 (S.Q.T.), P01HL142494 (B.P.K.) and DP2CA281401 (B.P.K.).

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.